Ruochuan Cheng

Prof. Dr. Ruochuan Cheng


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YCYihebali Chi
Yihebali Chi
XZXiangqian Zheng
Xiangqian Zheng
YZYuan Zhang
Yuan Zhang
FSFeng Shi
Feng Shi
YCYing Cheng
Ying Cheng
MGMing Gao
Ming Gao
Purpose: Alhough antiangiogenic agents are the bedrock of treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), novel antiangiogenic agents with optimized features like greater target-binding affinities and more favorable pharmacokinetics profile are needed. This phase II randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of anlotinib, a multikinase inhibitor, for RAIR-DTC. Patients and Methods: Patients (ages between 18 and 70 years) with pathologically confirmed locally advanced or metastatic RAIR-DTC were enrolled and randomly received 12 mg anlotinib once daily or placebo on day 1 to 14 every 3 weeks. Patients on placebo were allowed to receive open-label anlotinib after disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS) and safety. Results: Between September 2015 and August 2018, 76 and 37 patients randomly received anlotinib and placebo, respectively. Patients receiving anlotinib had a significantly longer median PFS [40.5 months, 95% confidence interval (CI), 28.3–not estimable (NE) versus placebo 8.4 months, 95% CI, 5.6–13.8; HR = 0.21, 95% CI, 0.12–0.37, P < 0.001], meeting the primary endpoint. OS was still immature, with a trend of benefit with anlotinib (HR = 0.57, 95% CI, 0.29–1.12). All patients in the anlotinib group experienced adverse events (AE); 8 (10.5%) discontinued treatment due to AEs. Conclusions: Anlotinib demonstrated promising efficacy and favorable tolerance in the treatment of locally advanced or metastatic RAIR-DTC, supporting further research to establish its role in the treatment of this serious disease.

11 March 2025 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CLChunmei Li
Chunmei Li
PWPei Wang
Pei Wang
ZDZhizhong Dong
Zhizhong Dong
WCWeihan Cao
Weihan Cao
YSYanjun Su
Yanjun Su
WLWEN LIU
WEN LIU
Objective: Active surveillance (AS) offers a viable alternative to surgical intervention for the management of indolent papillary thyroid carcinoma (PTC), helping to minimize the incidence of unnecessary treatment. However, the broader adoption of AS is hindered by the need for more reliable diagnostic markers. This study aimed to identify the differences between indolent and progressive PTC and find new targets for biomarker development and therapeutic strategies. Methods: We used single-cell RNA sequencing (scRNA-seq) to analyze cellular differences in 10 early-stage PTC tumors. Findings were validated in an additional 25 tumors using cell co-culture, migration assays, immunofluorescence staining, flow cytometry, and analysis of data from The Cancer Genome Atlas (TCGA). Results: Tumor-infiltrating B cells (TIL-B), particularly germinal center B cells (GC-B), were more abundant in indolent PTC. These cells suppressed thyroid cell proliferation in both indolent and progressive cases, though indolent PTC had a higher capacity to recruit peripheral B cells. In indolent cases, TIL-B cells showed increased proliferation and formed clusters within tertiary lymphoid structures (TLS). PTPRC-CD22 interactions were identified as potential drivers of TIL-B cell proliferation. Markers linked to GC-B cells, such as LMO2, were highlighted as potential diagnostic and prognostic indicators for indolent PTC. Conclusion: This study provides insights into the cellular landscape of early-stage PTC, revealing distinct tumor and immune microenvironment features in indolent and progressive cases. These findings advance the understanding of indolent PTC biology and support the development of reliable diagnostic and prognostic biomarkers.

1 October 2017 in Medicine
Verified
Journal Article
Open access
WLWen Liu
Wen Liu
RCRuochuan Cheng
Ruochuan Cheng
YSYanjun Su
Yanjun Su
CDChang Diao
Chang Diao
JQJun Qian
Jun Qian
YFYinxia Fan
Yinxia Fan
Due to the lack of an accurate preoperative diagnostic method of central lymph node metastasis (CLNM) of papillary thyroid cancer (PTC), the prophylaxis of central lymph node dissection remains controversial. The present study investigated the clinicopathological features of PTC patients and the risk factors of CLNM. The clinicopathological features of PTC patients with respect to sex, age, initial symptoms, observation, tumor diameter, multifocality, extrathyroidal invasion, and pathological data combined with other thyroid diseases, were analyzed retrospectively. The risk factors of CLNM were analyzed by Chi-squared test and multivariate logistic regression model. The CLNM rate of PTC was 40.6% (1331/3273). On average, 7.0 (4.0, 12.0) central lymph nodes were dissected, and 3.70 (±3.8) lymph nodes were proved to be metastatic. Univariate analysis showed that sex (P < .001), age (P < .001), tumor diameter (P < .001), extrathyroid invasion (P < .001), multifocality (P = .001), concurrent nodular goiter (P < .001), initial symptoms (P < .001), and observation or not (P < .001) were related to CLNM. The observation time was neither related to CLNM (P = .469) nor extrathyroidal invasion (P = .137). Tumors localized in the lower part of the thyroid were the risk factors for CLNM (P < .001) while multifocality was unrelated (P = .68). The metastasis rate of bilateral multiple regions > unilateral multiple regions > single region (P = .003). Multivariate logistic regression analysis showed that sex, age, tumor diameter, extrathyroidal invasion, and observation were independent risk factors of CLNM. Male, younger age, large tumor size, and extrathyroidal invasion were independent risk factors for CLNM. CLNM was related to multiple regions occupied by tumors in the thyroid but unrelated to multifocality. The tumor occupying a single region and localized in the lower part of thyroid could be used as a predictive factor for CLNM. For tumors that could not be diagnosed as benign or malignant, observation may be an option, since no evidence of disease progression was presented during observation.

30 April 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
XLXiang Li
Xiang Li
HZHanwen Zhang
Hanwen Zhang
YZYu Zhou
Yu Zhou
RCRuochuan Cheng
Ruochuan Cheng
Background: To investigate the influence of different risk factors on central lymph node metastasis (CLNM) in the cervical region in patients with papillary thyroid carcinoma (PTC). Methods: This retrospective study included 2586 PTC patients. Potential risk factors were identified by univariate analysis, and the relationships between these factors and CLNM were ascertained by multivariable analysis. A scoring system was constructed, and the optimal cut-off value was determined. Results: On univariate analysis, sex, age, tumor diameter, multifocality, capsule invasion, vascular invasion, total number of lymph nodes in the central region, and serum thyroid peroxidase antibody (TPOAb) concentration were identified as potential risk factors for CLNM in the cervical region, whereas nerve invasion, thyroid-stimulating hormone concentration, and thyroglobulin antibody (TgAb) concentration were not. Multivariable analysis indicated that male sex, young age, large tumor diameter, multifocality, vascular invasion, a large number of central lymph nodes, and a low TPOAb concentration were significant risk factors. From these factors, a preoperative CLNM risk assessment scale was constructed for predicting CLNM in the cervical region for PTC patients. Conclusion: Male sex, young age, large tumor diameter, multifocality, vascular invasion, a large number of central lymph nodes, and a low TPOAb concentration were positively correlated with CLNM in the cervical region in PTC patients. The preoperative CLNM risk assessment scale based on these risk factors is expected to offer accurate preoperative assessment of central lymph node status in PTC patients.

3 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WLWen Liu
Wen Liu
RCRuochuan Cheng
Ruochuan Cheng
YMYunhai Ma
Yunhai Ma
DWDan Wang
Dan Wang
YSYanjun Su
Yanjun Su
JLJin Liu
Jin Liu
Early preoperative diagnosis of central lymph node metastasis (CNM) is crucial to improve survival rates among patients with papillary thyroid carcinoma (PTC). Here, we analyzed clinical data from 2862 PTC patients and developed a scoring system using multivariable logistic regression and testified by the validation group. The predictive diagnostic effectiveness of the scoring system was evaluated based on consistency, discrimination ability, and accuracy. The scoring system considered seven variables: gender, age, tumor size, microcalcification, resistance index >0.7, multiple nodular lesions, and extrathyroid extension. The area under the receiver operating characteristic curve (AUC) was 0.742, indicating a good discrimination. Using 5 points as a diagnostic threshold, the validation results for validation group had an AUC of 0.758, indicating good discrimination and consistency in the scoring system. The sensitivity of this predictive model for preoperative diagnosis of CNM was 4 times higher than a direct ultrasound diagnosis. These data indicate that the CNM prediction model would improve preoperative diagnostic sensitivity for CNM in patients with papillary thyroid carcinoma.

30 April 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
ZDZhizhong Dong
Zhizhong Dong
XZXiangxiang Zhan
Xiangxiang Zhan
WLWen Liu
Wen Liu
DRDewei Rao
Dewei Rao
MYMiao Yang
Miao Yang
RCRuochuan Cheng
Ruochuan Cheng
Purpose: While the prognosis for differentiated thyroid cancer (DTC) is favorable, the health-related quality of life (QOL) of survivors is not well understood. This study aims to investigate the factors influencing the QOL of DTC survivors.Methods: A total of 860 DTC survivors who underwent thyroidectomy were surveyed. Participants completed the Chinese version of the Thyroid Cancer-Specific Quality of Life (THYCA-QOL) questionnaire, the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire-C30 (EORTC QLQ-C30), and additional related questions. Multivariate regression analyses identified factors affecting survivors’ QOL.Results: Among the survivors, 65 patients (7.6%) reported long-term postoperative complaints, including fatigue, throat discomfort, neck/shoulder stiffness, weight gain, and insomnia, among others. The average THYCA-QOL summary score was 20.29, with the highest scores in problems with scar, psychological problems, gained weight, less interest in sex, and sympathetic problems. The average EORTC QLQ-C30 summary score was 82.59, with lower scores for emotional and cognitive on the functional scales, and higher scores for fatigue and insomnia on the symptom scales. Women, BMI ≥ 28, higher T-stage (T3 + 4), permanent hypoparathyroidism, recurrence reoperation, and more postoperative complaints were associated with poorer thyroid cancer-specific QOL, while age over 45 years was associated with better QOL. Longer postoperative follow-up (>6 months) and drinking were correlated with higher QLQ-C30 summary scores, while recurrence reoperation and postoperative complaints were associated with worse QOL.Conclusions: The QOL of DTC survivors is influenced by multiple factors, with some patients experiencing long-term complaints. Attention to the QOL and postoperative complaints in DTC survivors is essential.